Notable shifts within regulatory frameworks and company strategies are shaping the biotech sector's future. FDA’s Center for Biologics Evaluation and Research witnessed the departure of Vinayak Prasad amid controversies over gene therapy approvals, notably Sarepta’s Duchenne muscular dystrophy treatment, with analysts forecasting benefits for cell and gene therapy stocks. Related editorial commentary signals a probable pivot toward libertarian regulatory approaches. Meanwhile, Eli Lilly announced the sale of its Branchburg, New Jersey monoclonal antibody manufacturing facility to realign production toward complex biologics, underscoring evolving pharmaceutical manufacturing priorities.